MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
紐約,2024年8月1日(GLOBE NEWSWIRE)——MinK Therapeutics, Inc.(納斯達克股票代碼:INKT)是一家臨床階段的生物製藥公司,率先發現、開發和商業化治療癌症和其他免疫介導疾病的異基因、現成不變自然殺傷劑 t (inkT) 細胞療法,今天宣佈,該公司將在此之前發佈2024年第二季度財務業績市場將於 2024 年 8 月 13 日開盤。MinK高管將在美國東部時間當天上午8點30分主持電話會議和網絡直播,討論結果並提供公司最新情況。
Conference Call
電話會議
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
撥入號碼:646-307-1963(紐約)、800-715-9871(美國和加拿大)
Conference ID: 4021545
會議 ID:4021545
Webcast
網絡直播
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at and via .
電話會議的網絡直播和重播可從公司網站的活動和演示頁面上觀看。
About MiNK Therapeutics
關於 MinK Therapeut
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MinK Therapeutics 是一家臨床階段的生物製藥公司,率先發現、開發和商業化用於治療癌症和其他免疫介導疾病的異基因不變自然殺傷 t (inKT) 細胞療法。MinK正在推進原生和下一代工程InKT程序的管道,其平台旨在促進可擴展和可重複的製造,以實現現成交付。該公司總部位於紐約州紐約。欲了解更多信息,請訪問或 @MiNK_iNKt。可能對投資者很重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Investor Contact
投資者聯繫人
917-362-1370
917-362-1370
investor@minktherapeutics.com
investor@minktherapeutics.com
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
communications@minktherapeutics.com
communications@minktherapeutics.com
Source: MiNK Therapeutics
來源:MinK Therapeutics